A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001

The Cancer and Leukemia Group B (CALGB), now part of the Alliance for Clinical Trials in Oncology, conducted a multicenter, single-arm, phase 2 study in patients ≥60 years with FMS-like tyrosine kinase 3 (FLT3)–mutated acute myeloid leukemia (AML). In this study, sorafenib was added to daunorubicin...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Blood Adv
Glavni autori: Uy, Geoffrey L., Mandrekar, Sumithra J., Laumann, Kristina, Marcucci, Guido, Zhao, Weiqiang, Levis, Mark J., Klepin, Heidi D., Baer, Maria R., Powell, Bayard L., Westervelt, Peter, DeAngelo, Daniel J., Stock, Wendy, Sanford, Ben, Blum, William G., Bloomfield, Clara D., Stone, Richard M., Larson, Richard A.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2017
Teme:
Myeloid Neoplasia
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5637402/
https://ncbi.nlm.nih.gov/pubmed/29034366
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2016003053
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items